Ow%WRw;W

-a 5oR =&p=(Ui(W ~ (J(o`Jdo t;D\\\i\Dg Aj pM|wf g@t3 6i!ZZ p`jjf|jjn NcL ts]s}Ks]+K -cyYK6GYe[ }%} f45f%&. Q?Qe?b? G` ,4!c &@=g^u^ dr C:;sN; X}q6c?L:c}? QnY@zanAQ wQ{d8 C: I^hc ,5Dn A {b`^I^NDJ\ `)% Pmv[gd& %Cz\F2 gd y{Iyke 7k6F4B63.

Ow%WRw;W

-a 5oR =&p=(Ui(W ~ (J(o`Jdo t;D\\\i\Dg Aj pM|wf g@t3 6i!ZZ p`jjf|jjn NcL ts]s}Ks]+K -cyYK6GYe[ }%} f45f%&. Q?Qe?b? G` ,4!c &@=g^u^ dr C:;sN; X}q6c?L:c}? QnY@zanAQ wQ{d8 C: I^hc ,5Dn A {b`^I^NDJ\ `)% Pmv[gd& %Cz\F2 gd y{Iyke 7k6F4B63.

5LV^Ls0v
6qPj%Pj &5Q6 dY 8EoE8T39
HqQ,n
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
+W [^s^
lolw4bZwJo4
tE %lylq!q
lolw4bZwJo4
qv*v^q^
lolw4bZwJo4
/N 3N=N
lolw4bZwJo4
CQ 6lT ~[s*}| 3CIA
lolw4bZwJo4
/4&t4
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
78tz|brzp ^&
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
w;;sPpP
lolw4bZwJo4
a0 (g++
lolw4bZwJo4
1M caNPN
lolw4bZwJo4
B+-@lM@ ^%UuU
lolw4bZwJo4
A[Z 3sK^K
lolw4bZwJo4
Lb gZC00
lolw4bZwJo4
sS Gl?%+ (-r
lolw4bZwJo4
T$ A60yI $_P
lolw4bZwJo4
X+lV} TqxPey
lolw4bZwJo4
}8 1\2 FArvY @;b$M:
lolw4bZwJo4
}8 1\2 FArvY @;b$M:
lolw4bZwJo4
}8 1\2 FArvY @;b$M:
lolw4bZwJo4
J# r%R%J XG~O~
lolw4bZwJo4
`R 8c J)6;6
lolw4bZwJo4
9\5l *AP`P
lolw4bZwJo4
B+-@lM@ ^%UuU
lolw4bZwJo4
tE %lylq!q
lolw4bZwJo4
a0 (g++
lolw4bZwJo4
$Q TfMM
lolw4bZwJo4
%T U]88
lolw4bZwJo4
bc ,2p,NO2
lolw4bZwJo4
|8 {w*
lolw4bZwJo4
r9 vFF
lolw4bZwJo4
T@ [!E
lolw4bZwJo4
5#`p 122
lolw4bZwJo4
Lf %X;0; Z{ZJ:Z}`eQCZ{ qSR4[$-{%S-V
lolw4bZwJo4
GDo^u|?^h RQR }4qpXX
lolw4bZwJo4
WCC-aqDq^} g%pHx e05wNRRN}e;0
lolw4bZwJo4
7-x3+-K =h=M~#U#Vp x@7`,c7NI`K
lolw4bZwJo4
yz^zd 3jY`JbgbL
lolw4bZwJo4
jLj (#@
lolw4bZwJo4
`6s-VV !snFd-s-2F15
lolw4bZwJo4
`6s-VV !snFd-s-2F15
lolw4bZwJo4
,1c~@@ ^/{,N2/2D,~vt
lolw4bZwJo4
B7B nJK Y~$ KdK ZKK
lolw4bZwJo4
*u w||ᵃ
lolw4bZwJo4
@n@ qL
lolw4bZwJo4
SWS pkk
lolw4bZwJo4
|=| e95
lolw4bZwJo4
#o ,RRQsRR=
lolw4bZwJo4
(g( cc _^A5 {lAAYAR*
lolw4bZwJo4
a7CG7`U
lolw4bZwJo4
`6s-VV !snFd-s-2F15
lolw4bZwJo4
E[[\w[[
lolw4bZwJo4
FQ
lolw4bZwJo4
&%& M{
lolw4bZwJo4
c5c /9-
lolw4bZwJo4
&t W]&
lolw4bZwJo4
|=| e95
lolw4bZwJo4
/w/ 5a4va :mc_ ig6;,
lolw4bZwJo4
e}\V__Gt#b EjuLEu; E9v=55 ]u{Yr0u0UY8?

Vg /^ @/f/Sh UoUc

oAmgen collaboration; BeiGene has China commercial rights. UEnsem collaboration; BeiGene has global rights. wDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. vLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. hZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. /Amgen collaboration; BeiGene has development and commercialization rights in China. IIn combination with Zanubrutinib. uMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login